Transcription Factor Rational Design Improves Directed Differentiation of Human Mesenchymal Stem Cells Into Skeletal Myocytes
Transcription Factor Rational Design Improves Directed Differentiation of Human Mesenchymal Stem Cells Into Skeletal Myocytes
- Research Article
36
- 10.1038/mt.2008.16
- Apr 1, 2008
- Molecular Therapy
Genetic Complementation of Human Muscle Cells via Directed Stem Cell Fusion
- Research Article
124
- 10.1038/mt.2009.67
- Jun 1, 2009
- Molecular Therapy
Enhancement of Myogenic and Muscle Repair Capacities of Human Adipose–derived Stem Cells With Forced Expression of MyoD
- Discussion
126
- 10.1038/mtna.2014.6
- Mar 1, 2014
- Molecular Therapy. Nucleic Acids
What Can We Learn From Clinical Trials of Exon Skipping for DMD?
- Research Article
81
- 10.1016/j.omtn.2017.02.007
- Feb 28, 2017
- Molecular Therapy - Nucleic Acids
CRISPR/Cas9-Mediated Genome Editing Corrects Dystrophin Mutation in Skeletal Muscle Stem Cells in a Mouse Model of Muscle Dystrophy.
- Research Article
88
- 10.1038/sj.mt.6300295
- Dec 1, 2007
- Molecular Therapy
Autologous Transplantation of SM/C-2.6+ Satellite Cells Transduced with Micro-dystrophin CS1 cDNA by Lentiviral Vector into mdx Mice
- Research Article
40
- 10.1016/j.isci.2019.11.001
- Nov 6, 2019
- iScience
Cytoplasmic RNA Sensor Pathways and Nitazoxanide Broadly Inhibit Intracellular Mycobacterium tuberculosis Growth.
- Research Article
56
- 10.1016/j.neuron.2013.06.002
- Jun 1, 2013
- Neuron
Remodeling Neurodegeneration: Somatic Cell Reprogramming-Based Models of Adult Neurological Disorders
- Front Matter
78
- 10.1016/j.metabol.2013.11.009
- Nov 19, 2013
- Metabolism
Irisin in humans: recent advances and questions for future research
- Research Article
47
- 10.1074/jbc.m110.180174
- Feb 1, 2011
- Journal of Biological Chemistry
Telomere maintenance is essential for protecting chromosome ends. Aberrations in telomere length have been implicated in cancer and aging. Telomere elongation by human telomerase is inhibited in cis by the telomeric protein TRF1 and its associated proteins. However, the link between TRF1 and inhibition of telomerase elongation of telomeres remains elusive because TRF1 has no direct effect on telomerase activity. We have previously identified one Pin2/TRF1-interacting protein, PinX1, that has the unique property of directly binding and inhibiting telomerase catalytic activity (Zhou, X. Z., and Lu, K. P. (2001) Cell 107, 347-359). However, nothing is known about the role of the PinX1-TRF1 interaction in the regulation of telomere maintenance. By identifying functional domains and key amino acid residues in PinX1 and TRF1 responsible for the PinX1-TRF1 interaction, we show that the TRF homology domain of TRF1 interacts with a minimal 20-amino acid sequence of PinX1 via hydrophilic and hydrophobic interactions. Significantly, either disrupting this interaction by mutating the critical Leu-291 residue in PinX1 or knocking down endogenous TRF1 by RNAi abolishes the ability of PinX1 to localize to telomeres and to inhibit telomere elongation in cells even though neither has any effect on telomerase activity per se. Thus, the telomerase inhibitor PinX1 is recruited to telomeres by TRF1 and provides a critical link between TRF1 and telomerase inhibition to prevent telomere elongation and help maintain telomere homeostasis.
- Research Article
75
- 10.1038/sj.mt.6300081
- Apr 1, 2007
- Molecular therapy : the journal of the American Society of Gene Therapy
Efficient Whole-body Transduction with Trans-splicing Adeno-associated Viral Vectors
- Research Article
220
- 10.1038/mt.2010.2
- Apr 1, 2010
- Molecular Therapy
A Transposon and Transposase System for Human Application
- Research Article
47
- 10.1074/jbc.m109.093963
- Sep 1, 2010
- Journal of Biological Chemistry
Hepatitis B virus X protein (pX), implicated in hepatocarcinogenesis, induces DNA damage because of re-replication and allows propagation of damaged DNA, resulting in partial polyploidy and oncogenic transformation. The mechanism by which pX allows cells with DNA damage to continue proliferating is unknown. Herein, we show pX activates Polo-like kinase 1 (Plk1) in the G(2) phase, thereby attenuating the DNA damage checkpoint. Specifically, in the G(2) phase of pX-expressing cells, the checkpoint kinase Chk1 was inactive despite DNA damage, and protein levels of claspin, an adaptor of ataxia telangiectasia-mutated and Rad3-related protein-mediated Chk1 phosphorylation, were reduced. Pharmacologic inhibition or knockdown of Plk1 restored claspin protein levels, Chk1 activation, and p53 stabilization. Also, protein levels of DNA repair protein Mre11 were decreased in the G(2) phase of pX-expressing cells but not with Plk1 knockdown. Interestingly, in pX-expressing cells, Mre11 co-immunoprecipitated with transfected Plk1 Polo-box domain, and inhibition of Plk1 increased Mre11 stability in cycloheximide-treated cells. These results suggest that pX-activated Plk1 by down-regulating Mre11 attenuates DNA repair. Importantly, concurrent inhibition of Plk1, p53, and Mre11 increased the number of pX-expressing cells with DNA damage entering mitosis, relative to Plk1 inhibition alone. By contrast, inhibition or knockdown of Plk1 reduced pX-induced polyploidy while increasing apoptosis. We conclude Plk1, activated by pX, allows propagation of DNA damage by concurrently attenuating the DNA damage checkpoint and DNA repair, resulting in polyploidy. We propose this novel Plk1 mechanism initiates pX-mediated hepatocyte transformation.
- Research Article
92
- 10.1038/mt.2009.49
- Aug 1, 2009
- Molecular therapy : the journal of the American Society of Gene Therapy
Rational Design of Antisense Oligomers to Induce Dystrophin Exon Skipping
- Research Article
68
- 10.1038/mt.2009.253
- Jan 1, 2010
- Molecular Therapy
Dystrophin Delivery to Muscles of mdx Mice Using Lentiviral Vectors Leads to Myogenic Progenitor Targeting and Stable Gene Expression
- Research Article
67
- 10.1074/jbc.m110.104125
- Apr 1, 2010
- Journal of Biological Chemistry
MutSβ (MSH2-MSH3) mediates repair of insertion-deletion heterologies but also triggers triplet repeat expansions that cause neurological diseases. Like other DNA metabolic activities, MutSβ interacts with proliferating cell nuclear antigen (PCNA) via a conserved motif (QXX(L/I)XXFF). We demonstrate that MutSβ-PCNA complex formation occurs with an affinity of ∼0.1 μm and a preferred stoichiometry of 1:1. However, up to 20% of complexes are multivalent under conditions where MutSβ is in molar excess over PCNA. Conformational studies indicate that the two proteins associate in an end-to-end fashion in solution. Surprisingly, mutation of the PCNA-binding motif of MutSβ not only abolishes PCNA binding, but unlike MutSα, also dramatically attenuates MutSβ-MutLα interaction, MutLα endonuclease activation, and bidirectional mismatch repair. As predicted by these findings, PCNA competes with MutLα for binding to MutSβ, an effect that is blocked by the cell cycle regulator p21CIP1. We propose that MutSβ-MutLα interaction is mediated in part by residues ((L/I)SRFF) embedded within the MSH3 PCNA-binding motif. To our knowledge this is the first case where residues important for PCNA binding also mediate interaction with a second protein. These findings also indicate that MutSβ- and MutSα-initiated repair events differ in fundamental ways.